Bicyclic aza compounds as muscarinic m1 receptor antagonists
AssigneeHeptares Therapeutics Limited
InventorsGiles Albert Brown, Julie Elaine Cansfield, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5, X1, X2 and p are as defined herein.
Claims10
1-18. (canceled)
A compound of the formula:
- or a salt thereof, wherein:
- X1 and X2 are saturated hydrocarbon groups which together contain a total of five to nine carbon atoms and which link together such that the moiety:
- forms a bicyclic ring system;
- R1 is selected from 2-methylpropyl;
- 2,2-dimethylpropyl;
- tert-butyl;
- 2-methyl-but-2-yl;
- 2,3-dimethylbut-2-yl;
- cyclopropylmethyl;
- cyclobutylmethyl;
- cyclopentyl;
- cyclopentylmethyl;
- 1-methylcyclobutyl;
- 1-methylcyclopentyl;
- 1-methylcyclohexyl;
- 1-methylcyclopentylmethyl;
- cyclopropyl-prop-2-yl;
- 1-methylcyclobutylmethyl and 1-ethyl-cyclobutylmethyl groups;
- R2 is selected from hydrogen, methyl, ethyl and isopropyl;
- or R1 and R2 together with the nitrogen atom to which they are attached form a non-aromatic heterocyclic ring of four to nine ring members, wherein the heterocyclic ring may optionally contain a second heteroatom selected from O, N and S and oxidised forms thereof;
- and wherein the heterocyclic ring may optionally be substituted with one to six substitutents selected from C1-2 alkyl;
- fluorine;
- and cyano;
- R3 is selected from hydrogen, fluorine and methoxy;
- and
- R4 is a C1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof.
A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.